Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Abe

Showing results (531-540 of 623) with videos related to

Pageof 63
Sort By:
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Comparison of chemotherapy with or without medroxyprogesterone acetate for advanced or recurrent breast cancerT Tominaga, O Abe, A Ohshima, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|January 1, 1989
[Acute promyelocytic leukemia with a history of RAEB in transformation and the 15/17 translocation]K Ogawa, H Shineha, R Abe, et al.
Gan No Rinsho. Japan Journal of Cancer Clinics|August 1, 1986
[Burkitt's lymphoma of the bilateral breasts presenting during lactation]T Nomizu, A Tsuchiya, T Nemoto, et al.
Oncology|May 27, 1999
A randomized controlled comparative study of oral medroxyprogesterone acetate 1,200 and 600 mg in patients with advanced or recurrent breast cancerH Koyama, T Tominaga, K Asaishi, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|November 1, 1994
[Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent breast cancer]T Taguchi, S Mori, R Abe, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|March 1, 1995
[Long-term clinical study on TAP-144-SR, an LH-RH agonist depot formulation, in premenopausal patients with advanced or recurrent breast cancer. TAP-144-SR Breast Cancer Study Group]T Taguchi, H Koyama, K Yayoi, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1992
Correlation of eosinophilia with clinical response in patients with advanced carcinoma treated with low-dose recombinant interleukin-2 and mitomycin CS Arinaga, N Karimine, K Takamuku, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|March 1, 1991
[Multihospital co-operative study of post-operative adjuvant chemotherapy in the treatment of gastric cancer-(Part 3). Comparisons between tegafur and UFT. North Kyushu Co-operative Study Group for Cancer Chemotherapy]S Arima, H Yamamoto, T Hisatsugu, et al.
Japanese Journal of Cancer Research : Gann|November 1, 1989
Mass screening for breast cancer: comparison of the clinical stages and prognosis of breast cancer detected by mass screening and in out-patient clinicsJ Ota, T Horino, T Taguchi, et al.
Cancer Investigation|January 1, 1994
Laboratory correlates of chemoimmunotherapy with low-dose recombinant interleukin-2 and mitomycin C in patients with advanced carcinomaS Arinaga, N Karimine, K Takamuku, et al.
Pageof 63

Showing results (531-540 of 623) with videos related to

Sort By:
Pageof 63
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Comparison of chemotherapy with or without medroxyprogesterone acetate for advanced or recurrent breast cancerT Tominaga, O Abe, A Ohshima, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|January 1, 1989
[Acute promyelocytic leukemia with a history of RAEB in transformation and the 15/17 translocation]K Ogawa, H Shineha, R Abe, et al.
Gan No Rinsho. Japan Journal of Cancer Clinics|August 1, 1986
[Burkitt's lymphoma of the bilateral breasts presenting during lactation]T Nomizu, A Tsuchiya, T Nemoto, et al.
Oncology|May 27, 1999
A randomized controlled comparative study of oral medroxyprogesterone acetate 1,200 and 600 mg in patients with advanced or recurrent breast cancerH Koyama, T Tominaga, K Asaishi, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|November 1, 1994
[Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent breast cancer]T Taguchi, S Mori, R Abe, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|March 1, 1995
[Long-term clinical study on TAP-144-SR, an LH-RH agonist depot formulation, in premenopausal patients with advanced or recurrent breast cancer. TAP-144-SR Breast Cancer Study Group]T Taguchi, H Koyama, K Yayoi, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1992
Correlation of eosinophilia with clinical response in patients with advanced carcinoma treated with low-dose recombinant interleukin-2 and mitomycin CS Arinaga, N Karimine, K Takamuku, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|March 1, 1991
[Multihospital co-operative study of post-operative adjuvant chemotherapy in the treatment of gastric cancer-(Part 3). Comparisons between tegafur and UFT. North Kyushu Co-operative Study Group for Cancer Chemotherapy]S Arima, H Yamamoto, T Hisatsugu, et al.
Japanese Journal of Cancer Research : Gann|November 1, 1989
Mass screening for breast cancer: comparison of the clinical stages and prognosis of breast cancer detected by mass screening and in out-patient clinicsJ Ota, T Horino, T Taguchi, et al.
Cancer Investigation|January 1, 1994
Laboratory correlates of chemoimmunotherapy with low-dose recombinant interleukin-2 and mitomycin C in patients with advanced carcinomaS Arinaga, N Karimine, K Takamuku, et al.
Pageof 63